TICKERNERD
Menu
CLYMCLYMHealthcare · Biotechnology

CLYM Stock Forecast: Climb Bio, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$10
−0.19% on the day

The 15 Wall Street analysts covering Climb Bio, Inc. hold a median 12-month price target of $27 — +157.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 14 Oct 2026 — in the upper half.

Market cap
$622.0M
Ticker Nerd rank
66 / 100
Median analyst target
$27
Analysts covering
15
Revenue$0.0
Operating income−$15.4M
Net income−$13.5M
Free cash flow−$10.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
−29.3%
YTD
+157.2%
1Y
+447.3%
From 52W high
−42.3%
From 52W low
+527.4%
$2
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLYM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Climb Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
66 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Revisions
68
Value
63
Volatility
60
Quality
60
Issuance
56
Size
50
Accruals
35
Growth
32

Momentum (91): The shares have been drifting up relative to others.

Growth (32): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLYM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLYM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26CLYMHigh $40Median $27Low $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
15 Buy0 Hold0 Sell
Low $18Median $27High $40

The green dot is the last close — the median target sits +157.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
8 Sept 2026HC Wainwright & Co.MaintainsBuy$24 → $30
8 Sept 2026OppenheimerMaintainsOutperform$18 → $25
4 Sept 2026B. Riley SecuritiesReiteratesBuy$26 → $30
3 Sept 2026BairdMaintainsOutperform$21 → $25
3 Sept 2026BTIGMaintainsBuy$20 → $32
24 Aug 2026HC Wainwright & Co.MaintainsBuy—
24 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $24
19 Aug 2026WedbushReiteratesOutperform—
19 Aug 2026WedbushReiteratesOutperform$20
7 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026Truist SecuritiesMaintainsBuy$17 → $25
27 July 2026WedbushMaintainsOutperform$17 → $20
27 July 2026WedbushMaintainsOutperform—
24 June 2026HC Wainwright & Co.ReiteratesBuy$20
24 June 2026HC Wainwright & Co.ReiteratesBuy—
12 June 2026WedbushReiteratesOutperform—
11 June 2026BTIGMaintainsBuy—
8 June 2026BTIGReiteratesBuy—
8 June 2026GuggenheimInitiatesBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLYM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CLYM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Climb Bio, Inc. returned +447.3% against +17.5% for the S&P 500, dividends included.

CLYM vs S&P 500, last 12 monthsTotal return, rebased to 100
02004006008001,000Jan 26Apr 26Jul 26Oct 26CLYMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CLYM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Climb Bio, Inc. (CLYM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.3×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
2.6×

Cheaper than 35% of US stocks

EV / EBITDA
−6.8×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−27.1%

Higher than 28% of US stocks

Return on assets
−18.5%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Climb Bio, Inc. (CLYM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Climb Bio, Inc. has a market value of $622.0M and an enterprise value of $440.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$57.6M.

  • Diluted earnings per share, trailing twelve months: $−0.83.

  • Free cash flow in the twelve months to 30 June 2026: −$53.1M.

  • Shares outstanding: 57.4M.

  • Trailing P/E: −12.3×; forward P/E: −10.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Climb Bio, Inc. employs 28 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

CLYM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CLYMClimb Bio, Inc.$622.0M
66
OLMAOlema Pharmaceuticals, Inc.$592.7M
26
WVEWave Life Sciences, Inc.$594.5M
14
PHATPhathom Pharmaceuticals, Inc.$579.4M
82
DSGNDesign Therapeutics, Inc.$600.1M
59
ZVRAZevra Therapeutics, Inc.$600.6M
99
CRMDCorMedix, Inc.$576.0M
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Climb Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLYM news & analysis

Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval

Seeking Alpha · 7 Oct 2026neutral

The Seeking Alpha excerpt highlights Climb Bio’s CLYM116 and budoprutug, noting modeled quarterly dosing for CLYM116, CD19 differentiation for budoprutug, and $239.2 million in cash providing runway into the second half of 2028. It also points to competitive and execution risks for both assets.

Why it matters — CLYM watchers may weigh the stated product differentiators and cash runway against clinical execution and competition risks.

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

GlobeNewsWire · 2 Oct 2026positive

Climb Bio announced it will present new data at the American Society of Nephrology (ASN) Kidney Week 2026 for its drug candidates CLYM116 and budoprutug. Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy has been selected for oral presentation.

Why it matters — The selection of budoprutug's Phase 2 data for an oral presentation at a major nephrology conference provides visibility into the company's lead clinical program for CLYM watchers.

Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug

MarketBeat · 3 Sept 2026positive

Climb Bio presented Phase I data for CLYM116, an anti-APRIL "sweeper" antibody being developed for IgA nephropathy. The company said the results support advancing the program into an ongoing Phase II study in China.

Why it matters — The data validate CLYM116's development path and support progress of the company's lead pipeline candidate toward Phase II.

Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule

Benzinga · 3 Sept 2026positive

Climb Bio released preliminary data from its ongoing Phase 1 trial of CLYM116 and announced updated strategic plans for treating IgA nephropathy, a kidney disease. The news includes support for an extended dosing schedule for the therapy.

Why it matters — This marks progress in Climb Bio's lead kidney disease program with preliminary trial data and a refined development strategy for IgA nephropathy.

Why Climb Bio, Up 1,300% Over 17 Months, Just Skidded

Investors Business Daily · 3 Sept 2026negative

Climb Bio shares reversed course Thursday, falling despite potentially "best-in-class" data for its experimental kidney disease treatment. The stock had previously risen more than 1,300% over 17 months.

Why it matters — The stock's sharp reversal despite encouraging trial data signals investor concerns that could affect Climb Bio's valuation and momentum.

FAQ

Frequently asked questions about CLYM stock

What is the CLYM stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Climb Bio, Inc. have a median 12-month price target of $27, with estimates ranging from $18 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLYM stock a buy right now?

Of the 15 analysts covering Climb Bio, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Climb Bio, Inc. 66 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLYM?

As at 14 Oct 2026, Climb Bio, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will CLYM stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +157.5% from the last close, and Ticker Nerd's factor model ranks Climb Bio, Inc. 66 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLYM stock forecast for 2030?

No analyst covering Climb Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLYM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $40 over the next 12 months.

How has CLYM stock performed over the past year?

Climb Bio, Inc. returned +447.3% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Climb Bio, Inc. do?

Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing monoclonal antibody therapies for immune-mediated diseases.

What is the latest news on CLYM?

The most recent item we track (Seeking Alpha, 7 Oct 2026): "Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval". The Seeking Alpha excerpt highlights Climb Bio’s CLYM116 and budoprutug, noting modeled quarterly dosing for CLYM116, CD19 differentiation for budoprutug, and $239.2 million in cash providing runway into the second half of 2028. It also points to competitive and execution risks for both assets.

Company

About Climb Bio, Inc.

Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing monoclonal antibody therapies for immune-mediated diseases. Its current pipeline centers on budoprutug, an anti-CD19 antibody being studied for B-cell mediated and autoantibody-driven conditions, and CLYM116, an anti-APRIL antibody in development for IgA nephropathy. The company’s work is directed at diseases where abnormal immune activity can damage organs and create significant unmet medical need, including kidney and hematologic disorders. Climb Bio operates in the biopharmaceutical sector through preclinical research, clinical development, and translational programs designed to advance differentiated biologic medicines. Based in Wellesley Hills, Massachusetts, Climb Bio is positioned as a specialized developer of targeted immunology assets for complex immune disorders.

CEO Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc · 28 employees · United States · https://climbbio.com